BioMerieux (FRA:EYWN) Total Receivables: €826 Mil (As of Dec. 2025)


FRA:EYWN BioMerieux SA FRA:EYWN
66 GF Score
Price €69.60
GF Value €109.06
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Total Receivables?

BioMerieux FRA:EYWN -1.83% 66 Total Receivables is €826 Mil as of Dec. 2025. GuruFocus rates FRA:EYWN with a GF Score™ of 66/100 and a GF Value™ of €109.06 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMerieux's Total Receivables for the quarter that ended in Dec. 2025 was €826 Mil.

BioMerieux Total Receivables Historical Data

* Premium members only.

The historical data trend for BioMerieux's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMerieux Total Receivables Chart

BioMerieux Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 665.80 909.00 776.00 857.60 826.10

BioMerieux Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 776.00 888.60 857.60 893.10 826.10
FRA:EYWN
66GF Score
BioMerieux SA FRA:EYWN
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMerieux Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €826 Mil mean?
BioMerieux (FRA:EYWN) has a Total Receivables of €826 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on BioMerieux and its competitors.
Is BioMerieux's Total Receivables too high?
BioMerieux's current Total Receivables is €826 Mil. Overall, BioMerieux has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's Total Receivables compare to TMO and DHR?
BioMerieux's Total Receivables of €826 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Diagnostics & Research company?
A good Total Receivables depends on the Medical Diagnostics & Research industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on BioMerieux and its competitors. BioMerieux's current Total Receivables is €826 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (FRA:EYWN) is currently considered Significantly Undervalued. The stock's GF Value™ is €109.06, compared to a current price of €69.60 — trading 36.2% below its estimated fair value. The current Total Receivables is €826 Mil. BioMerieux's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For BioMerieux (FRA:EYWN), the current Total Receivables is €826 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMerieux (FRA:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €69.60 is trading 36.2% below its estimated GF Value™ of €109.06. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for FRA:EYWN:

  • Total Receivables: €826 Mil
  • GF Value™: €109.06 vs. price of €69.60 (36.2% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the FRA:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
66GF Score

Get the complete analysis for FRA:EYWN

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.60
Price
€109.06
GF Value